265 related articles for article (PubMed ID: 27880982)
1. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM
Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
3. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
6. The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.
Pescia C; Lopez G; Cattaneo D; Bucelli C; Gianelli U; Iurlo A
Leuk Res; 2024 Jan; 136():107420. PubMed ID: 38016412
[TBL] [Abstract][Full Text] [Related]
7. Splanchnic vein thrombosis in myeloproliferative neoplasms.
Sekhar M; McVinnie K; Burroughs AK
Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
[TBL] [Abstract][Full Text] [Related]
8. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
De Stefano V; Qi X; Betti S; Rossi E
Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
[TBL] [Abstract][Full Text] [Related]
9. Splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Tremblay D; Winters A; Beckman JD; Naymagon L; Patel R; Mascarenhas J; Schiano TD
Thromb Res; 2022 Oct; 218():8-16. PubMed ID: 35963121
[TBL] [Abstract][Full Text] [Related]
10. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
[TBL] [Abstract][Full Text] [Related]
12. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
13. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
Finazzi G; De Stefano V; Barbui T
Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
[TBL] [Abstract][Full Text] [Related]
14. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
15. γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.
Görtzen J; Hunka LM; Vonnahme M; Praktiknjo M; Kaifie A; Fimmers R; Jansen C; Heine A; Lehmann J; Goethert JR; Gattermann N; Goekkurt E; Platzbecker U; Brossart P; Strassburg CP; Brummendorf TH; Koschmieder S; Wolf D; Trebicka J
Medicine (Baltimore); 2016 May; 95(20):e3355. PubMed ID: 27196445
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
[TBL] [Abstract][Full Text] [Related]
19. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
How J; Zhou A; Oh ST
Ther Adv Hematol; 2017 Mar; 8(3):107-118. PubMed ID: 28246554
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
